Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials.

Change in ACT score Three studies with 688 participants reported the efficacy of omalizumab on the change in ACT, with a trend for improvement by 0.58 points (95% CI −0.12–1.29); however, they did not reach statistical significance or the MCID (three points for adults and two points for patients aged 12–18 years) ( supplementary figure S14 ) [ 67 , 68 ].

also in 111,027 other papers

Pneumonias 10 studies with 5550 participants (3239 on biologics) reported results on pneumonias during the study period, demonstrating that the use of biologics was associated with an overall trend of a 30% reduction of pneumonias compared to the control group (risk ratio 0.70, 95% CI 0.36–1.37, I 2 =0%) ( supplementary figure S22 ).

also in 4,871 other papers